• Publication Date: 06/01/2020
  • Author(s):
    Fink, James B. MacLoughlin, Ronan
  • Organization(s):
    Aerogen Limited Aerogen Pharma Corporation
  • Article Type: Technical Articles
  • Subjects: Devices and Components, Industry Issues and Trends, Nasal Delivery, Product Development/Formulation
With recent advances in devices and formulations, many more conditions are expected to be treatable with nasal delivery. Trans-nasal pulmonary administration remains in its infancy but is poised to grow as evidenced by its rapid adoption to routine use in many intensive care units worldwide. We believe the next decade should see significant advances in both.

Now, more than ever, healthcare economics are providing the impetus for innovation and consequently we will see some non-obvious disease states being treated using the nasal route. As we better understand the relationships of particle size, delivered gas, patient anatomy, and inspiratory patterns across patient populations, we expect more optimized pulmonary delivery efficiency, expanding trans-nasal methods in treatment of neonates, infants, toddlers and older adults with a variety of agents. With nasal and trans-nasal pulmonary delivery, we are at the cusp of an inflection point in two intrinsically connected, but very different fields of research and product development. We believe the next decade should see significant advances in both, further increasing the quality of life for patients, as well as offering significant value and opportunity for those groups willing to focus on them now.

Download PDF